PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Tablets”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 217 records · Page 12Linked to original sources

[On the Polymorphism of barbiturates in powders and tablets. Part 4: the dissolution of barbital B and barbital A (modifications I and III and their release from tablets (author's transl)].

Two commercial brands of barbital (A: German Democratic Republic, modification III; B: Hungarian Peopl's Republic, modification I) were used to study the solubility and dissolution of the modifications. Crystals of these two substances were brought into the shape of tablets, the physical parameters and textural properties of which were determined. The effect of polymorphism on the release of these substances is discussed in the light of the results obtained from this investigation. The discussion will be continued and summarized in a subsequent paper, including further modifications.

Barbital↗

[On the polymorphism of Barbiturates in powers and tablets. Part 5: The dissolution of recrystallized barbital substances and their release from tablet (author's transl)].

The dissolving characteristics of 6 different barbital modifications have been studied. With one exception, the metastable forms dissolved more rapidly than the stable form. The observed differences were not always significant. Substances recrystallized from an acetone-water mixture were less soluble in aqueous solvents than those recrystallized from water. The dissolving characteristics are changed by tabletting, the stable modification being more favourable in this respect. The solubility of barbital A2 was very poor. Consequently, it is not suited for therapeutic use. The dissolution rate was determined by means of the rotating basket method as described in the nineteenth edition of the U.S.P.

Barbital↗

A procedure for calibration transfer between near-infrared instruments--a worked example using a transmittance single tablet assay for piroxicam in intact tablets.

A procedure was developed for different modes of calibration transfer in near-infrared (NIR) spectroscopy, which included a method for the selection of a subset of samples appropriate for transfer. As a worked example, these guidelines were applied to the transfer of a multivariate calibration model, representing a validated NIR single tablet assay for the active within an intact pharmaceutical product, between three equivalent dispersive NIR transmission instruments. Transfer was first evaluated between two instruments, representing the situation where both were available during calibration development. A spectral correction method alone, applied to the transfer instrument, was not sufficient to facilitate transfer, with further optimisation of the calibration model using a novel wavelength selection algorithm necessary to remove regions of the spectral range that resulted in skewed predictions on the second instrument. Through this approach, a single calibration model was found to be equally accurate and precise on the two instruments. A procedure, using the Kennard-Stone algorithm, is described for determining a reduced number of samples as a transfer set using only the spectral information from the original instrument. The purpose of the subset was to permit transfer to a new instrument where that instrument was not available until after calibration development or where it was undesirable to re-measure the full sample set (i.e. due to excessive reference chemistry). Utilising the transfer set, transfer to a third instrument was evaluated. The calibration model, optimised between the first two instruments, was not directly applicable for the third instrument, with further wavelength selection required to remove a small region of spectral data. On completion, using a full statistical evaluation, a single calibration model was found to be equally accurate and precise on all three instruments.

Anti-Inflammatory Agents, Non-Steroidal↗

A comparative trial of two slow-release theophylline tablets in the treatment of asthma; Nuelin S.A. and Theocontin Continus tablets.

Twenty-five adult asthmatic patients were entered into a double-blind random crossover comparison of Theocontin Continus tablets with Nuelin S.A. The patients received additional therapy with inhaled salbutamol and/or beclomethasone diproprionate. Four patients withdrew because of persistent unwanted side-effects, nausea and headaches in three, and mental confusion in one, and a fifth withdrew for non-medical reasons. Analysis of the results of the remaining twenty patients showed no difference between the effects of the two preparations in symptom scoring, reduction in salbutamol inhaler use and improvement in respiratory function as measured by daily PEFR, at similar serum levels. The same dosage per kilogram for either preparation gave virtually identical mean serum levels suggesting there is no difference in the rate of absorption between the two preparations.

Adult↗

Evaluation of prochlorperazine buccal tablets (Bukatel) and metoclopramide oral tablets in the treatment of acute emesis.

The dizziness associated with vertiginous disorders is often accompanied with nausea and/or vomiting. Antiemetic effect of prochlorperazine (PCZ) is diminished by its low bioavailability owing to a significant gastric and hepatic first pass effect. This effect could be further diminished by likelihood of regurgitation of nauseating patients further limiting the therapeutic effect of oral PCZ. A buccal preparation achieves higher plasma concentrations through direct systemic absorption. In this study buccal prochlorperazine (Bukatel) was compared for its efficacy and tolerability with commonly used metoclopramide. Bukatel was well tolerated and well rated by both patients and investigators with no adverse effects on buccal mucosa and causing less drowsiness and sedation. Results indicate that Bukatel is safe and effective for the treatment of nausea and/or vomiting in patients suffering from vertiginous disorders and could be safely and strongly recommended as an alternative to less bioavailable and indiscriminately used oral metoclopramide tablets.

Administration, Buccal↗

Antihypertensive effect and tolerability of felodipine extended release (ER) tablets in comparison with felodipine plain tablets (PT) and placebo in hypertensives on a diuretic. Canadian Study Group.

Antihypertensive efficacy and tolerability of felodipine extended release (ER) (o.d.), felodipine plain tablet (PT) (b.i.d.), and placebo were compared in mild to moderate hypertensives whose seated diastolic blood pressure (DBP) was > or = 95 mm Hg while on hydrochlorothiazide 25 mg od. In addition to the diuretic, patients were randomised to felodipine ER 5 mg od (n = 50), PT 2.5 mg bid (n = 50), or placebo (n = 48) for 6 weeks, with clinic visits every 2 weeks. If seated DBP was > or = 90 mm Hg at any visit, daily dosage of felodipine was doubled to a maximum of 20 mg. The mean difference between ER and placebo was 5.1 mm Hg (p = 0.003); for PT vs. placebo the difference was 5.3 mm Hg (p = 0.002). Seated systolic blood pressure (SBP) was reduced by a mean difference of 6.8 mm Hg in the felodipine PT group compared with placebo (p = 0.03). Fourteen patients were withdrawn: 4 from the placebo group, 4 from the felodipine ER group, and 6 from the felodipine PT group. The most commonly reported adverse event was peripheral edema. In patients not adequately controlled on diuretic alone, felodipine ER o.d. and felodipine PT b.i.d. were superior to placebo in reducing seated DBP.

Adult↗